In November 2020 Congenica completed a $50m Series C funding round, with plans in place to accelerate international market development and driving further expansion of Congenica’s product platform into somatic cancer, wellness and through partnerships with pharmaceutical companies.
Furthermore, Congenica will deliver advanced capabilities including the ability to integrate with existing electronic health systems and deliver fully automated genomic data interpretation capability, building a future where personalized decisions and treatments, guided by genomic information, can be routinely used to transform the health and wellness of individuals around the world.
Take a look at this video where, Congenica’s CEO, David Atkins PhD, and Chairman, Andy Richards OBE, tell you more about Congenica and our plans for the future.